Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Spero starts Phase I trial of SPR720 for NTM infections

SPR720 is an orally administered antibacterial agent that aims to treat non-tuberculous mycobacterial infections. Credit: ec-jpr.



  • Spero Therapeutics

Go Top